Insider Buying: Bausch Health Cos Inc. (NYSE:BHC) Director Buys $21,170,510.46 in Stock

Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) Director John Paulson purchased 3,564,059 shares of the stock in a transaction on Friday, June 13th. The shares were purchased at an average cost of $5.94 per share, for a total transaction of $21,170,510.46. Following the acquisition, the director now directly owns 32,791,702 shares of the company's stock, valued at approximately $194,782,709.88. This represents a 12.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

John Paulson also recently made the following trade(s):

• On Thursday, June 12th, John Paulson acquired 1,005,376 shares of Bausch Health Cos stock. The stock was acquired at an average price of $5.47 per share, for a total transaction of $5,499,406.72.
• On Wednesday, June 11th, John Paulson bought 1,029,098 shares of Bausch Health Cos stock. The shares were acquired at an average cost of $5.24 per share, for a total transaction of $5,392,473.52.
• On Tuesday, June 10th, John Paulson purchased 754,134 shares of Bausch Health Cos stock. The shares were purchased at an average cost of $5.05 per share, with a total value of $3,808,376.70.

Bausch Health Cos Stock Performance

Bausch Health Cos stock traded down $0.03 during trading hours on Friday, hitting $6.15. The company had a trading volume of 1,782,863 shares, compared to its average volume of 2,579,084. The firm has a market cap of $2.27 billion, a P/E ratio of -55.87 and a beta of 0.28. The company has a 50-day moving average price of $4.94 and a two-hundred day moving average price of $6.37. Bausch Health Cos Inc. has a 1 year low of $3.96 and a 1 year high of $9.85.

Institutional Trading of Bausch Health Cos

Large investors have recently modified their holdings of the company. Toronto Dominion Bank lifted its holdings in shares of Bausch Health Cos by 1.0% in the 4th quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock worth $1,350,000 after buying an additional 1,712 shares during the period. Wells Fargo & Company MN lifted its stake in Bausch Health Cos by 7.9% in the fourth quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock worth $209,000 after acquiring an additional 1,896 shares during the period. American Century Companies Inc. grew its holdings in Bausch Health Cos by 10.6% during the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock worth $220,000 after acquiring an additional 2,600 shares in the last quarter. Blair William & Co. IL increased its position in Bausch Health Cos by 3.2% during the 4th quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock valued at $683,000 after purchasing an additional 2,622 shares during the period. Finally, SBI Securities Co. Ltd. raised its holdings in shares of Bausch Health Cos by 244.2% in the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after purchasing an additional 3,001 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on BHC shares. Wall Street Zen downgraded Bausch Health Cos from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. Royal Bank Of Canada boosted their price objective on Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to data from MarketBeat, Bausch Health Cos currently has a consensus rating of "Hold" and an average target price of $7.42.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.